The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Chocolate is used as a flavoring product in many desserts, such as chocolate cakes, chocolate brownies, chocolate mousse and chocolate chip cookies. Numerous types of candy and snacks contain chocolate, either as a filling (e.g., M&M's) or as a coating (e.g., chocolate-coated raisins or chocolate-coated peanuts). Some non-alcoholic beverages contain chocolate, such as chocolate milk, hot chocolate, chocolate milkshakes and tejate. Some alcoholic liqueurs are flavored with chocolate, such as chocolate liqueur and crème de cacao. Chocolate is a popular flavor of ice cream and pudding, and chocolate sauce is a commonly added as a topping on ice cream sundaes. The caffè mocha is an espresso beverage containing chocolate.
Vitamin D deficiency was found to be related to neurological manifestations and the presence of lymphoma among patients. Vitamin A levels were inversely associated with extraglandular manifestations of the disease. Saliva is a potential diagnostic tool for Sjögren's disease because the salivary component is changed after the onset of the disease. With the new miniaturization technology, called lab on a chip, the diagnosis can be more convenient. Concerning therapeutics, multiple monoclonal antibodies were under investigation in 2007. The most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014, the Sjögren's Foundation (previously the Sjögren's Syndrome Foundation) announced a five-year goal to halve the disease's average time to diagnosis. As of 2026, several investigational therapies were in late-stage clinical development for Sjögren's disease. In January 2026, the FDA granted ianalumab Breakthrough Therapy designation for Sjögren's disease. Other agents in phase III development include telitacicept and dazodalibep.
Heritable connective tissue diseases are rare, each disorder estimated at one to ten per 100,000, of which Marfan syndrome is the most common. It is carried by the FBN1 gene on chromosome 15, which encodes the connective protein fibrillin-1, inherited as a dominant trait. This protein is essential for synthesis and maintenance of elastic fibers. Since these fibers are particularly abundant in the aorta, ligaments, and the ciliary zonules of the eye, these areas are among the worst affected. Everyone has a pair of FBN1 genes and, because transmission is dominant, those who have inherited one affected FBN1 gene from either parent will have Marfan syndrome. Although it is most frequently inherited as an autosomal dominant, there is no family history in 25% of cases. Recruiting practices aimed at attracting athletes who are unusually tall or who have an unusually wide arm span (characteristics of Marfan syndrome) can increase the prevalence of the syndrome within sports such as basketball and volleyball.
In China and Korea, lotus leaf tea (Korean: 연잎차; RR: yeonnipcha) is made from the leaves of the lotus. Lotus leaves are also used to serve food in various cultures. It is used as a wrap for steaming rice and sticky rice and other steamed dishes in Asian cuisines, such as lo mai gai and zongzi in Chinese cuisine, kao hor bai bua (Thai: ข้าวห่อใบบัว) fried rice wrapped in lotus leaf in Thai cuisine. Vietnamese also use lotus leaves to wrap green young rice, cốm, which is eaten in autumn. The leaves impart a unique scent to the soft, moist rice.
Sources: en.wikipedia.org
=== Hardware === The technology made by Dionex includes the Rapid Separation LC (RSLC) and polymeric HPLC columns, a type of monolithic HPLC column. Unlike the inorganic silica columns, the polymer monoliths are made of an organic polymer base. Dionex, traditionally known for its ion chromatography capabilities, has led this side of the field. Dionex first acquired a license for the polymeric monolith technology in the 1990s. Dionex also acquired ESA Biosciences' HPLC assets in 2009, expanding its expertise in this area.
The Christian New Testament notes that some people thought that Jesus was, in some sense, Elijah, but it also makes clear that John the Baptist is "the Elijah" who was promised to come in Malachi 3:1; 4:5. According to accounts in all three of the Synoptic Gospels, Elijah appeared with Moses during the Transfiguration of Jesus. In Western Christianity, Elijah is commemorated as a saint with a feast day on 20 July by the Roman Catholic Church and the Lutheran Church–Missouri Synod. Catholics believe that he was unmarried and celibate. In the Eastern Orthodox Church and those Eastern Catholic Churches which follow the Byzantine Rite, he is commemorated on the same date (in the 21st century, Julian Calendar 20 July corresponds to Gregorian Calendar 2 August). He is greatly revered among the Orthodox as a model of the contemplative life. He is also commemorated on the Orthodox liturgical calendar on the Sunday of the Holy Fathers (the Sunday before the Nativity of the Lord). John the Baptist is also known as John the Forerunner in Christianity, John the Immerser in some Baptist Christian traditions, He is considered to be a prophet of God by all of these faiths, and is honoured as a saint in many Christian denominations. According to the New Testament, John anticipated a messianic figure greater than himself, and the Gospels portray John as the precursor or forerunner of Jesus, since John announces Jesus' coming and prepares the people for Jesus' ministry.
== Artwork == The original album cover consisted of a collage of autopsy photographs collected from medical journals. It has been said that the cover artwork "feature[s] real life abnormalities, grotesqueries and decomposition," and that "it's like a Where's Waldo? of gore... You find something new every time you look at it!" Reek of Putrefaction was re-released in 1994 with a "clean" cover. In 2002, the album was reissued with a censored outer cover proclaiming "Original artwork contained inside".
Sources: en.wikipedia.org
Tequila's color ranges from clear to a brownish amber, depending on the aging process and the type of wood used for storage. The white (blanco) version of tequila, also nicknamed "silver", is the product with no aging, or may be aged less than two months. It is the purest form, as little has been done to change it. What is known as gold, joven or oro tequila is usually white tequila with the addition of grain alcohols and caramel color; some higher-end gold tequilas may be a blend of white and reposado. Rested (reposado) tequila is aged for a relatively short time (two months or more), and aged (añejo) tequila for a longer time (a year or more). All aging of tequila is done in wooden containers. The aging process can last three years or more, and can create or enhance flavors and aromas. It generally imparts a golden color.
=== Laboratory tests === Serum creatine kinase (CK) is the most commonly used biomarker of muscle injury, and is often supplemented by aldolase, lactate dehydrogenase and the aminotransferases. However, elevated CK is not specific to myopathy, and isolated raised CK ("hyperCKemia") has a poor diagnostic yield on its own. Where an idiopathic inflammatory myopathy is suspected, testing for myositis-specific autoantibodies (MSAs) is recommended, ideally before starting immunosuppression, as these antibodies define distinct clinical subtypes and patterns of organ involvement.
== Production == The series is a Movistar Plus+ original, produced in collaboration with Suma Content. Shooting locations in Catalonia included Barcelona, Girona, Mataró, Òrrius, Santa Eulàlia de Ronçana, Calaf, Arenys de Mar, Manresa, Gualba, and Santa Susanna. The series was lensed by Gris Jordana. Raül Refree (score) and Hidrogenesse (original songs) were responsible for the music.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.